

Thermo Fisher enhances clinical research solutions in collaboration with Matrix Clinical Trials

20 April 2022 | News

Mobile research sites ease barriers to patient participation, improve trial enrollment

The PPD clinical research business of Thermo Fisher Scientific Inc. and Matrix Clinical Trials, a Matrix Medical Network offering, are collaborating to bring clinical trials to patients with an innovative decentralized clinical trial (DCT) solution.

The business is deploying state-of-the-art Matrix mobile research sites and expert clinical staff across the U.S. to help identify, recruit and retain trial participants, while ensuring a positive patient experience. At the same time, the two companies are exploring opportunities to expand the collaboration to additional geographies.

Thermo Fisher's clinical research business is the only clinical research organization (CRO) to use Matrix's virtual principal investigator network coupled with mobile sites as a stand-alone transportable clinical trial operation. The collaboration demonstrates Thermo Fisher's continuing commitment to advance decentralized trial solutions for customers and patients.

It provides flexible decentralized trial solutions developed across multiple therapeutic areas. The goal is to increase patient diversity and access, and to improve the patient experience, resulting in time efficiencies and data quality enhancements that can help speed development timelines.